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Abstract
In metagenomic studies, testing the association of microbiome composition and clinical outcomes 
translates to testing the nullity of variance components. Motivated by a lung HIV (human 
immunodeficiency virus) microbiome project, we study longitudinal microbiome data by variance 
component models with more than two variance components. Current testing strategies only apply 
to the models with exactly two variance components and when sample sizes are large. Therefore, 
they are not applicable to longitudinal microbiome studies. In this paper, we propose exact tests 
(score test, likelihood ratio test, and restricted likelihood ratio test) to (1) test the association of the 
overall microbiome composition in a longitudinal design and (2) detect the association of one 
specific microbiome cluster while adjusting for the effects from related clusters. Our approach 
combines the exact tests for null hypothesis with a single variance component with a strategy of 
reducing multiple variance components to a single one. Simulation studies demonstrate that our 
method has correct type I error rate and superior power compared to existing methods at small 
sample sizes and weak signals. Finally, we apply our method to a longitudinal pulmonary 
microbiome study of human immunodeficiency virus (HIV) infected patients and reveal two 
interesting genera Prevotella and Veillonella associated with forced vital capacity. Our findings 
shed lights on the impact of lung microbiome to HIV complexities. The method is implemented in 
the open source, high-performance computing language Julia and is freely available at https://
github.com/JingZhai63/VCmicrobiome.
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1 Introduction
Technology advances have led to a much deeper understanding of microbes and their link to 
human health (Eckburg et al., 2005; Haas et al., 2011; Hodkinson and Grice, 2015; Kuleshov 
et al., 2016; Wang and Jia, 2016). In particular, for the pulmonary microbiome, Rogers et al. 
(2010) hypothesized that microbial lung community might exist and can be considered as a 
unique, distinct pathogenic entity. The culture-independent microbial detection method, 16S 
ribosomal RNA (rRNA) gene sequencing, demonstrated the existence of pulmonary 
microbiome, both in healthy (Erb-Downward et al., 2011; Morris et al., 2013; Twigg et al., 
2013) and disease populations (Zemanick et al., 2011; Lozupone et al., 2013).
This paper is motivated by longitudinal microbiome studies. For instance, the lung HIV 
(human immunodeficiency virus) microbiome project studies the respiratory microbiome of 
HIV-infected patients and how the highly active antiretroviral therapy (HAART) may alter 
its construction (Twigg III et al., 2016). A longitudinal cohort of HIV-infected subjects were 
collected before and up to three years after starting HAART. For a quantitative phenotype in 
a longitudinal design, we propose the model
y = Xβ + Zb + h(G) + ε, (1)
b ∼𝒩(0, σd
2In), h(G) ∼𝒩(0, σg
2K), ε ∼𝒩(0, σe
2In),
where y, X, G and ε are the vertically stacked vectors/matrices of individual-level yi, Xi, Gi 
and εi. yi is a vector of ni repeated measures of a quantitative phenotype for individual i. Xi 
is the ni × p covariate matrix. Gi is an ni × u Operational Taxonomic Unit (OTU) abundance 
matrix for individual i where u is the total number of OTUs. These OTUs are related by a 
known phylogenetic tree. εi is an ni × 1 vector of the random error. Z is a block diagonal 
matrix with 1ni
 on its diagonal. β is a p × 1 vector of fixed effects and b = (bi) is the subject-
specific random effects. K is a kernel matrix capturing distances between individuals, e.g., 
the UniFrac distance (Lozupone and Knight, 2005) or the Bray-Curtis dissimilarity (Bray 
and Curtis, 1957) (Web Appendix A). b, h(G) and ε are jointly independent; therefore,
Var(y) = σd
2ZZ′ + σg
2K + σe
2In, (2)
where σd
2
 is the phenotypic variance due to the correlation of repeated measurements, σg
2
 is 
the phenotypic variance explained by microbiome, and σe
2
 is the within-subject variance that 
cannot be explained by microbiome and repeated measurements. Detection of overall 
microbiome association is to test H0: σg
2
 = 0 versus HA: σg
2
 > 0. When σd
2
 = 0, model (1) 
reduces to the microbiome regression-based kernel association test (MiRKAT) (Zhao et al., 
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2015; Chen et al., 2016; Zhan et al., 2017). In the longitudinal setting, the extra variance 
component σd
2
 is necessary to capture the correlation between repeated measurements.
After the overall association is identified, localization of the signal to a specific component 
of the microbial community is essential for downstream mechanistic studies and drug 
discoveries. For instance, Jangi et al. (2016) found that multiple sclerosis patients had 
significantly increased abundance of the phylum Euryarchaeota. However, such fine cluster 
effects can be tagged by other correlated microbial in the community (Gilbert et al., 2016), 
leading to false positive discoveries. To detect association from specific taxonomic clusters, 
distances and kernel matrices can be formulated using abundances and tree information from 
specific clusters. Overall microbiome effects are then partitioned into different clusters at the 
same taxonomic level. That is
Var(y) = σd
2ZZ′ +
i
σgi
2 Ki + σe
2In, (3)
where 
i
σgi
2 Ki is the summation of all microbiome clusters. We are now interested in testing 
effects from a specific taxonomic cluster: H0: σgi
2 = 0 versus HA: σgi
2 > 0.
Current methods for testing null variance component in models (2) and (3) are based on 
either asymptotics or parametric bootstrap. Under the assumption that the response variable 
vector can be partitioned into independent subvectors and the number of independent 
subvectors is sufficient, asymptotic null distribution of the likelihood ratio, Wald, and score 
tests are available (Self and Liang, 1987; Stram and Lee, 1994; Silvapulle and Sen, 2011). 
However, the asymptotic approximation deteriorates when the data are highly correlated 
without a sufficient number of independent blocks. Let m be the total number of phenotypic 
variance components except error variance component. When m = 1, Crainiceanu and 
Ruppert (2004) developed a computational procedure for obtaining the approximate finite-
sample distribution of the likelihood ratio and restricted likelihood ratio test statistics. 
Greven et al. (2008) provided a pseudolikelihood-heuristic extension of this method to the m 
> 1 situation. Later Drikvandi et al. (2013) proposed a permutation test that does not depend 
on the distribution of the random effects and errors except for their mean and variance and 
can be applied to the m > 1 situation. However, the permutation test is computationally 
prohibitive for high dimensional tests. Qu et al. (2013) proposed a test statistic that is the 
weighted sum of the scores from the profile likelihood. Their method considered testing a 
subset of the variance components to be zero. When m = 1, Qu et al. (2013)’s method is 
exact; when m > 1, their test relies on asymptotic theory. Score-based tests can be less 
powerful than the likelihood ratio tests, especially when sample sizes are limited as in most 
of the sequencing studies. Saville and Herring (2009) developed yet another type of test 
based on the Bayes factors using Laplace approximation. It cannot be easily extended to 
multiple random effects, and relies on the subjective choice of the prior distribution of 
parameters. Others have suggested procedures based on Markov chain Monte Carlo methods 
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(Chen and Dunson, 2003; Kinney and Dunson, 2007), but they can be time-consuming, 
especially when the number of random effects is large.
In this article, we propose methods of performing exact Likelihood Ratio Test (eLRT), exact 
Restricted Likelihood Ratio Test (eRLRT), and exact Score test (eScore) of a variance 
component being zero for the finite sample. Our approach combines the corresponding exact 
tests for the m = 1 case with a strategy of reducing the m > 1 case to the m = 1 case 
(Ofversten, 1993; Christensen, 1996). Our method is the first one that provides eLRT, 
eRLRT, and eScore for testing zero variance component when multiple variance 
components are present (m > 1).
2 Methods
2.1 Exact tests with one variance component under H0
We briefly review the three exact tests, eLRT, eRLRT, and eScore, for testing H0: σ1
2 = 0 in 
model
V = σe
2In + σ1
2V1 . (4)
Note the change of notation for general modeling. In the motivating microbiome example, 
σ1
2 = σg
2
 and V1 = K, the kernel matrix calculated from microbiome abundances. A slight 
extension allows for testing the more general case V = σe
2V0 + σ1
2V1, where V0 ∈ ℝ
n × n
 is a 
known positive semidefinite matrix. Let t = rank(V0). Given the thin eigen-decomposition 
V0 = UDU′, define T = D
−1/2U′ ∈ ℝt × n. (Only t column vectors of U will be computed in 
thin eigen-decomposition.) Then T y ∼𝒩(TXβ, σe2It + σ12TV1T′) and the eLRT and eRLRT 
(Crainiceanu and Ruppert, 2004) or the eScore test (Zhou et al., 2016) can be applied to Ty.
Let λ = σ1
2/σe
2
 be the signal-to-noise ratio, s = rank(X), and write the covariance as 
V = σe
2(In + λV1) = σe
2Vλ. The model parameters are (β, σe2, λ). Testing H0: σ12 = 0 is 
equivalent to testing H0: λ = 0. The log-likelihood function is 
L(β, σe
2, λ) =     − n2   lnσe
2 − 12 lndet(Vλ) −
1
2σe
2 (y − Xβ)′Vλ
−1(y − Xβ). The likelihood ratio test 
(LRT) statistic is
LRT = 2sup
HA
L(β, σe
2, λ) − 2sup
H0
L(β, σe
2, λ)
= sup
λ ≥ 0
{nlny′A0y − nlny′Aλy − lndet(Vλ)}
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where PX = X(X′X)
−1X′ is the projection matrix onto the column space 𝒞(X), A0 = I − PX 
and Aλ = Vλ
−1 − Vλ
−1X(X′Vλ
−1X) − X′Vλ
−1
. Let ξ1,…, ξℓ  be the positive eigenvalues of V1 
and μ1,…, μk  the positive eigenvalues of A0V1A0. Then
LRT =𝒟 sup
λ ≥ 0
nln i = 1
n − s
ωi
2
i = 1
k
ωi
2
1 + λμi
+
i = k + 1
n − s
ωi
2
− ∑
i = 1
l
ln(1 + λξi) ,
where, under the null, wi are (n−s) independent standard normals. Under the alternative, 
ωi ∼𝒩(0, 1 + λμi) for i = 1, …, k, wi ∼ 𝒩 (0, 1) for i = k + 1,…, n − s, and they are jointly 
independent. The null distribution can be obtained from computer simulation. A 
computationally efficient χ2 approximation algorithm is given in the Supplementary 
Material (Web Appendix B). The same derivation can be carried out for the eRLRT, in which 
case
RLRT =D sup
λ ≥ 0
(n − s)ln i = 1
n − s
ωi
2
i = 1
k
ωi
2
1 + λμi
+
i = k + 1
n − s
ωi
2
− ∑
i = 1
k
ln(1 + λμi) .
The null distribution generation for eRLRT is shown in Web Appendix B. Algorithms 1 and 
2 in Web Appendix B contain a univariate optimization for each simulated point from the 
null distribution and can be computationally intensive for obtaining extremely small p-
values. To further reduce computational burden, we adopt the Satterthwaite method to 
approximate the null distributions (Zhou et al., 2016).
For eScore, it is easier to work with the original parameterization V = σe
2In + σ1
2V1. The 
(Rao) score statistic is based on I
σ1
2, σ1
2
−1 ∂
∂σ1
2 L
2
, where the information matrix 
I
σ1
2, σ1
2 = E −
∂2
∂σ1
2∂σ1
2 L  and score function 
∂
∂σ1
2 L are evaluated at the maximum likelihood 
estimator (MLE) under the null. The resultant test rejects the null when
S = max
y′(I − PX)V1(I − PX)y
y′(I − PX)y
, tr(K)n
is large. Let {μ1, …, μk} be the positive eigenvalues of (I − Px)V1(I − Px). Then
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S =D max i = 1
k
μiωi
2
i = 1
n − s
ωi
2
, tr(K)n ,
where wi are n − s independent standard normals. The null distribution can be obtained from 
computer simulation or inverting the characteristic function (Zhou et al., 2016). Both 
options, simulation and approximation of null distribution, are available in our program, 
https://github.com/JingZhai63/VCmicrobiome.
2.2 Exact tests with more than one variance components under H0
In this section we consider the situation when Y ~ N (Xβ, V ) with 
V = σ0
2I + σ1
2V1 + · · · + σm
2Vm, m > 1. We are interested in testing H0: σm
2 = 0 vs HA: σm
2 > 0. 
We follow a strategy to reduce the problem to the m = 1 case 2 (Ofversten, 1993; 
Christensen, 1996).
We first obtain an orthonormal basis (Q0, Q1,…, Qm, Qm+1) of ℝn such that Q0 is an 
orthonormal basis of C(X), Q1 is an orthonormal basis of C(X, V1) − C(X), Qi is an 
orthonormal basis of C(X, V1,…, Vi) − C(X, V1,…, Vi−1) for i = 2,…, m, and Qm+1 is an 
orthonormal basis of ℝn − C(X, V1,…, Vm). Denote their corresponding ranks by r0,…, rm+1. 
If rm > 0, that is C(X,V1,…,Vm −1)   ⊈ C(X,V1,…,Vm −1,Vm), then 
Q′mY ∼𝒩(0, σe
2Irm
+ σm
2Q′mVmQm) and eLRT, eRLRT and eScore can be applied to Q′mY. 
The order of V1,…, Vm does not matter. If rm = 0, that is C(X, V1,…, Vm−1) = C(X, V1,…, 
Vm), we construct a test based on the transformed data Q′m − 1Y + CQ′m + 1Y. Without loss of 
generality we assume Qm−1 is nontrivial. If rm−1 = 0, we use Qm−2 and so on. We consider 
the following cases:
1. If Q′m −1Vm = 0, e.g., when C(Vm) ⊂ C(X,V1,…,Vm −2), then this test cannot be 
performed. Shifting the order of X, V1,…,Vm−1 might solve the issue.
2. If Q′m −1Vm −1Qm −1 = γIrm − 1 and γ ≠       0, then
Q′m − 1Y ∼𝒩(0, σe
2Irm − 1 + σm − 1
2 Q′m − 1Vm − 1Qm − 1 + σm
2 Q′m − 1VmQm − 1)
=𝒩(0, σe
2 + γσm − 1
2 )Irm − 1
+ σm
2 Q′m − 1VmQm − 1
which is the case (4). eLRT, eRLRT and eScore can be applied without using the CQ′m+1y 
piece.
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1. If Q′m −1Vm −1Qm −1 ≠ γIrm − 1, then the test requires the CQ′m+1y term. 
CQ′m+1y as distribution CQ′m+1Y   ∼𝒩(0, σe
2CC′). Since Q′m−1Y ⊥ CQ′m + 1Y, 
we pick C such that
CC′ζ−1Qm − 1′ Vm − 1Qm − 1 − Irm − 1
,
where the scalar ζ is chosen such that ζ−1Q′m − 1Vm − 1Qm − 1 − Irm − 1 positive semidefinite. 
Let Q′m −1Vm −1Qm − 1 = WΛW′ = Wdiag δi W′ be the eigen-decomposition, ζ be the smallest 
positive eigenvalue, and C = Wdiag( δi/ζ − 1. Then the transformed data 
Q′m − 1Y + CQ′m + 1Y ∼𝒩(0, (σm
2   − 1 + σe
2/ζ)Q′m − 1Vm − 1Qm − 1 + σm
2Q′m − 1VmQm − 1)and 
the test for case (2.1) can be applied. A larger ζ leads to a higher signal-to-noise ratio 
σm
2
σm − 1
2 + σe
2/ζ
 and thus a more powerful test. Finally we test H0: σm
2 = 0 using eLRT, eRLRT or 
eScore test on the transformed data,
Λ−1/2W′(Q′m − 1 + CQ′m + 1)Y ∼𝒩(0, (σm − 1
2 + σe
2/ζ)Irm − 1
+ σm
2 Λ−1/2W′Q′m − 1VmQm − 1WΛ
−1/2)
We note that if in some applications that matrices have high or full rank, consuming most or 
all available degrees of freedom after above reduction strategy. One could proceed with a 
low rank approximation. For example, if m = 2 and V1 has high or full rank, one could find 
rank rV1 approximation of V1 as follows: let rK = rank(V2), Q0 is an orthonormal basis of 
C(X), and r0 = rank(Q0). A rank rV1 ≤
n − r0 − rK
2  approximation of V1 is suffice to 
perform testing. Details can be found in the software’s documentation (http://
vcmicrobiomejl.readthedocs.io/en/latest/).
3 Simulation
We evaluate the performance of the exact tests for longitudinal microbiome study in three 
simulation scenarios (Table 1).
Longitudinal microbiome count data with 2 repeated measurements are simulated using the 
R package ZIBR (Zero-Inflated Beta Random Effect model) (Chen and Li, 2016). To mimic 
features of real microbiome datasets, the phylogenetic structure and average count 
information are extracted from the real HIV longitudinal pulmonary microbiome data. This 
microbiome dataset contains 30 samples, each with 2 to 4 repeated measurements: baseline, 
4 weeks, 1 year and 3 years (Twigg III et al., 2016). OTU alignment at species level was 
produced by software Mothur (https://www.mothur.org/) (Schloss et al., 2009) and Basic 
Local Alignment Search Tool (BLAST) (https://blast.ncbi.nlm/.nih.gov/Blast.cg) (Altschul 
et al., 1990) in the Ribosomal Database Project (RDP) 16S database release 11.4 (Maidak et 
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al., 1996). The phylogenetic tree at the OTU level is generated using the RDP classifier 
(Twigg III et al., 2016). We construct the higher taxon level, e.g., phylum, using the 
phylogenetic tree generator phyloT (http://phylot.biobyte.de/) (Letunic and Bork, 2007, 
2011) and NCBI database taxonomy (https://www.ncbi.nlm.nih.gov/taxonomy) (Federhen, 
2012). There are 2964 operational taxonomic units (OTUs) in total, 292 genera, and 24 
phyla. Different distance measures are calculated using our Julia package 
PhylogeneticDistance (https://github.com/JingZhai63/PhylogeneticDistance.jl). The 
definition of different distance measures and the details of simulation of microbiome 
abundances are provided in Web Appendix A and C.
Phenotypes are generated under three different scenarios. For all three scenarios, two 
covariates are included in the model. One of them is correlated with microbiome 
abundances. For individual i, X1i ∼𝒩(0, 1) and X2i = h(Gi)baseline + N(0, 1). Their effects are 
β1 = β2 = 0.1. We set within-individual variance to σe2 = 1. For longitudinal data simulation, 
between individual variance σd
2
 is set to 0.6. This corresponds to 60% of overall baseline 
phenotypic variance (Twigg III et al., 2016).
Scenario 1: Testing overall microbiome effect.
Longitudinal responses are generated using model, y ∼𝒩(X1β1 + X2β2, σd
2ZZ′ + σg
2K + σe
2I), 
where σd
2
 = 0, 0.2, 0.5, 1.0 and 1.5. We compare the performance of five different distance 
measures: unweighted UniFrac (Lozupone and Knight, 2005), weighted UniFrac distance 
(Lozupone et al., 2007), variance adjusted weighted (VAW) UniFrac distance (Chang et al., 
2011), and generalized UniFrac distance with parameter α = 0.0 and 0.5 (Chen et al., 2012).
Scenario 2: Localizing fine microbiome cluster effects.
We cluster OTUs into 6 phyla, Actinobacteria, Bacteroidetes, Fusobacteria, Proteobacteria, 
Firmicutes, and other. We assume that only cluster other, h(G1i), has effects. That is 
y ∼𝒩(X1β1 + X2β2, σd
2ZZ′ + Σl = 1
6 σgl
2 Kl + σe
2I), where σg1
2
 = 0, 0.5, 1.5 and σg1
2 = 0 for l = 2,
…,6. Due to the correlation between phyla, marginal tests of 5 individual phylum may show 
false signal if we do not adjust for the effects of h(G1i). We present testing of variance 
components in a joint model has correct type I error.
Scenario 3: Comparing with existing methods.
We compare our method with MiRKAT (Zhao et al., 2015) and LinScore (Qu et al., 2013). 
As MiRKAT can only be used for testing overall microbiome effects for cross-sectional 
designs, we first compare three methods when σd
2 = 0. Responses are generated according to 
simulation scenario 1, where σg
2 = 0,…, 1.5.
In scenarios 1 and 2, the sample size is fixed at n = 100. In scenario 3, we compare the 
performance of three methods under sample sizes 20, 30, 50 and 100. The performance of 
five different kernels is compared in scenario 1. For scenarios 2 and 3, we focus on the 
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weighted UniFrac distance kernel only, which demonstrates higher power than other kernels 
in scenario 1. 1000 Monte Carlo replicates are generated for all simulations and we use the 
nominal significance level 0.05 to evaluate type I error and power.
4 Results
Simulation Results
Scenario 1: Testing overall microbiome effect.—The type I error rate of eRLRT, 
eLRT and eScore tests with various distance kernel matrices using real longitudinal OTU 
count data are shown in Table 2. Figure 1 shows the power comparison with different 
kernels. In Figures 1a and 1c, five different kernels are constructed using OTU count data 
directly. In Figures 1b and 1d, OTU counts are summarized at the phylum level for kernel 
calculations.
Figure 1 shows that kernel type greatly impacts the power. The weighted UniFrac kernel 
yields the highest power and the unweighted UniFrac kernel has the least power (Figures 1a 
and 1c). The pattern of the power increase with effect size differs according to which taxon 
level count data are used to calculate kernel. The power of five kernels became similar to 
each other in Figures 1b and 1d. Further, the power of unweighted UniFrac kernel KUW, 
which is the least powerful kernel in Figures 1a and 1c, greatly improves in Figures 1b and 
1d. The reason is when the reads are summarized at the higher phylum level, the difference 
of abundance between each phylum is less notable. The less variability of abundance 
between lineages, the more similar power of detecting microbiome association. As expected, 
reducing variance components leads to reduced degrees of freedom for association testing 
and the test is slightly less powerful in the longitudinal study compared to the cross-sectional 
study given the same effect size in this simulation.
Scenario 2. Localizing fine microbiome cluster effects.—Table 3 shows the type I 
error rates for testing microbiome effect at the phylum level, with and without adjusting for 
the effect contributed by cluster, other. Most type I error rates are inflated when not 
adjusting for cluster other effects. In cross-sectional design, the type I error rates of 
Bacteroidetes and Proteobacteria stay correct due to its weak correlation with cluster other 
(Pearson correlation = 0.04, 0.11 with p-value = 0.70, 0.24, respectively). After adjustment, 
type I error rates stay correct even when confounding effects are large (Table 3).
In practice, symbiosis of bacteria causes correlation between them (Xu et al., 2007; Dickson 
et al., 2013; Zeng et al., 2016). Precise medication that targets specific pathogens can 
minimize the damage to essential symbiotic microbial species, and preserve community 
structure and function in the healthy (and developing) microbiome (Hicks et al., 2013; 
Blaser, 2016). Simulation scenario 2 demonstrates that our method is capable of localizing 
fine microbiome cluster effects.
Scenario 3: Comparing to existing methods MiRKAT and LinScore.—Table 4 
presents type I error rate and power for eRLRT, eLRT, eScore, MiRKAT and LinScore tests 
in detecting overall microbiome effects. The power is shown for both cross-sectional and 
longitudinal studies with sample size from 20 to 100. eRLRT and eLRT outperform LinScore 
Zhai et al. Page 9
Genet Epidemiol. Author manuscript; available in PMC 2020 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
and MiRKAT in baseline simulation studies. For repeated measurements, eRLRT 
outperforms LinScore under small sample sizes (e.g., n ≤ 50). Under sample size n = 100, 
eRLRT has similar or slightly higher power comparing to LinScore when association 
strength is weak. Microbiome studies usually have limited sample size due to the high cost. 
Higher power of the exact tests at small sample sizes will be particularly valuable for 
biologists and physicians to identify the associated microbiome clusters.
Analysis of Longitudinal Pulmonary Microbiome Data
It is well-known that HIV infection is associated with alterations in the respiratory 
microbiome (Twigg III et al., 2016). However due to the limited investigation, the clinical 
implications of lung microbial dysbiosis are currently unknown. As an initial step to reveal 
the connection of respiratory microbiome to pulmonary complications in HIV-infected 
individuals, we investigate the relationship between pulmonary function and the respiratory 
microbiota profiles in the bronchoalveolar lavage (BAL) fluid of 30 HIV-infected patients at 
the advanced stage (baseline mean CD4 count, 262 cells/mm3). Their acellular BAL fluid 
was sampled at baseline, 4 weeks, 1 year, and 3 years. 16S rRNA gene sequencing 
technology was used to quantify pulmonary microbiota. Details of microbiome composition 
have been discussed in Section 3. Pulmonary function is measured by spirometry and 
diffusion capacity tests. Spirometry tests measure how much and how quickly air can move 
out of lung. Typical spirometry tests include forced vital capacity (FVC), forced expiratory 
volume in 1 second (FEV1), and average forced expiratory flow (FEF). Diffusion capacity of 
the lungs for carbon monoxide (DLCO) measures how much oxygen travels from lung 
alveoli to blood stream. DLCO corrected for hemoglobin (DsbHb) and diffusion capacity 
corrected for alveolar volume and hemoglobin (DVAsbHb) are evaluated. Descriptive 
statistics of these measures are summarized in Web Appendix Table 1.
Exact tests and LinScore are used to study the association. Associations with p-values less 
than 0.05 are reported to be significant. Covariates include gender, race, smoking status, 
CD4 counts, and HIV virus load (Table 5). Missing covariate is imputed by its mean. For 
overall microbiome association test, no tests find significant associations. However at the 
phylum level, Bacteroidetes shows significant association with spirometry while Firmicutes 
shows significant association with diffusing capacity measures. Similar results have been 
reported by Molyneaux et al. (2012) and Tunney et al. (2013). We then focus on analyzing 
genera from both phyla Bacteroidetes and Firmicutes given their important status in normal 
lungs (Cui et al., 2014). Only by eRLRT and eScore, genus Prevotella, Porphyromonas, and 
Parvimonas show significant effects on FEF and FEV1 (Table 5). Genus Veillonella shows 
significant association with FEF. It appears that both Parvimonas and Veillonella in phylum 
Firmicutes are significantly associated with FEF and both genus Prevotella and 
Porphyromonas in phylum Bacteroidetes are significantly associated with FEF and FEV1. 
We therefore perform the test in a joint model to localize fine cluster effect. Interestingly, by 
eRLRT the significant association between genus Parvimonas and FEF still remains after 
adjusting for the effects from genus Veillonella. But the opposite is not true. This supports 
the previous studies that Parvimonas abundance changed in subjects with pulmonary disease 
(e.g., asthma or COPD) comparing to the control group. (Pragman et al., 2012; Kim et al., 
2018) However, either Prevotella or Porphyromonas lost its significance when adjusting for 
Zhai et al. Page 10
Genet Epidemiol. Author manuscript; available in PMC 2020 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
the other. This likely suggests that Prevotella and Porphyromonas are correlated and both tag 
effects to lung function. In comparison, LinScore only detects the significant microbiome 
effect of Bacteroidetes with FEF. Our results further support the conclusions from previous 
studies and shed lights for future clinical causality research (Twigg III et al., 2016; Weiden 
et al., 2017; Segal et al., 2017). None of the tests (exact tests, LinScore, and MiRKAT) 
identify significant associations using only baseline data (results not shown). In conclusion, 
our exact tests provides innovative association evidence of pulmonary microbiome and lung 
function in HIV infected population, which have not been reported before. While the 
modeling is compelling, interpretation of the data and how correlations translate to 
meaningful clinical outcomes needs further study.
5 Discussion
In this report, motivated by a longitudinal pulmonary microbiome study, we develop and 
implement three computationally efficient exact variance component tests (eScore, eLRT, 
and eRLRT). Our method extend previous exact variance component tests to the case when 
the null hypothesis contains more than one variance component (Zhou et al., 2016). They 
can be applied to longitudinal studies testing the overall microbiome effects, as well as 
cross-sectional studies identifying microbiome associations at fine-grained level. The latter 
has been emerging as the focus of many current microbiome studies (Nayfach et al., 2016; 
Lloyd-Price et al., 2017; Truong et al., 2017). Unlike Qu et al. (2013) and Zhao et al. 
(2015)’s score test that uses moment-matching to approximate null distribution, our tests are 
exact in finite samples, therefore beneficial to the studies with limited sample size. 
Compared to score test, our eLRT and eRLRT tests can further boost power when 
microbiome effects are weak. Simulation studies verify that our exact tests have correct size 
and many innovative utilizations. In the application to the real longitudinal pulmonary 
microbiome study, only our exact tests detect multiple interesting genera associated with 
lung function. We then further demonstrate the ability of our exact tests to differentiate 
associated genus by two real data examples. Although the derivation of eLRT and eRLRT 
require normality assumption, a sensitivity simulation shows that even with a misspecified 
phenotypic distribution, like t-distribution, our tests still preserve correct type I error rate 
(Web Appendix E, Table 2). The software package is implemented in an open source, high-
performance computing language Julia and is freely available. We offer unweighted, 
weighted, variance adjusted weighted and generalized UniFrac distance calculation to 
further ease the computation and advance microbiome studies.
There are a few directions for future work. First, there are linear mixed effects models not of 
form (3), for example, those include both random intercepts and random slopes (Drikvandi 
et al., 2013). Our methods extend to these cases naturally and we defer them to future 
research. Second direction is to incorporate multiple types of kernels into exact tests. Last 
we consider extension to the generalized linear mixed effects models, although it can be 
challenging especially for LRT and RLRT. Score-based tests may be possible through 
penalized quasi-likelihood (PQL) (Lin, 1997; Chen et al., 2016).
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6 Software
A Julia package is freely available at https://github.com/JingZhai63/VCmicrobiome. In the 
real longitudinal data analysis with sample size 30 and 2964 OTUs, the elapsed CPU time 
are 0.1 seconds and 0.04 seconds for eRLRT and eScore, respectively. The analysis was 
performed by a MacBook Pro with 2.3GHz Intel Core i7 processor and 8GB 1600MHz 
DDR3 memory.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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FIGURE 1: 
Scenario 1: Power of eRLRT, eLRT and eScore using different distance measures. Figure to 
the left shows results where the OTU counts are used to calculate distances, figures to the 
right shows that OTU counts are summarized at phylum level to construct the distances. K0, 
K0.5, KW, KU and KV AW represent generalized UniFrac distance with α = 0, 0.5, weighted 
UniFrac distance, unweighted UniFrac distance and variance adjusted weighted UniFrac 
distance, respectively.
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TABLE 1
Simulation configurations. For all simulations, σe
1 = 2 and σd
2 = 0 when number of repeats (# Repeat) = 1 or 
σe
2 = 1 and σd
2 = 0.6 when number of repeats >1. There are 2964 OTUs presented in simulated count data. A 
phylogenetic tree generated using the real pulmonary microbiome data is used for kernel calculation and 
phenotype simulations. KW: weighted UniFrac kernel; KU: unweighted UniFrac kernel; KV AW: variance 
adjusted weighted UniFrac kernel; Kα: generalized UniFrac kernels with = 0 and 0:5.
Scenario 1: Testing overall microbiome effect
Sample size Kernel type Clustering # Repeat σg
2 Method
100 KW, KU, KV AW,
Kα
None 2 0 – 1.5 eRLRT eScore
100 KW, KU, KV AW,
Kα
None 1 0 – 1.5 eRLRT eLRT eScore
Scenario 2: Localizing fine microbiome cluster effects
Sample size Kernel type Clustering # Repeat σg
2 Method
100 KW Yes 2 0 – 1.5 eRLRT eScore
100 KW Yes 1 0 – 1.5 eRLRT eScore
Scenario 3: Comparing to existing methods
Sample size Kernel type Clustering # Repeat σg
2 Method
20; 30; 50; 100 KW None 2 0 – 1.5 eRLRT eScore
LinScore
20; 30; 50; 100 KW None 1 0 – 1.5 eRLRT eLRT eScore
LinScore MiRKAT
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TABLE 2
Scenario 1: Type I error of eLRT, eRLRT and eScore for detecting overall microbiome effects. Five distance 
measures, weighted UniFrac kernel (KW ), unweighted UniFrac kernel (KU ), variance adjusted weighted 
UniFrac kernel (KV AW ), and generalized UniFrac kernels with = 0 (K0) and 0:5 (K0:5) are compared.
Kernel Type
Simulation Design Method KW KU KV AW K0 K0.5
Cross-sectional eRLRT 0.046 0.043 0.045 0.048 0.047
eLRT 0.046 0.043 0.051 0.052 0.046
eScore 0.039 0.031 0.047 0.045 0.042
Longitudinal eRLRT 0.041 0.053 0.045 0.041 0.042
eScore 0.034 0.048 0.048 0.050 0.045
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TABLE 3
Scenario 2: Type I error rate of localizing fine microbiome cluster effects. Only cluster “Other” contains 
effects, 0, 0:5 and 1:5. Type I error rates are evaluated with or without adjustment for effect from cluster Other. 
The weighted UniFrac kernel is used. Top panel shows results from simulation using longitudinal data while 
bottom panel shows results using cross-sectional data only.
Longitudinal Design
No Adjustment for Other Adjustment for Other
Phylum Effect Size σg
2 Effect Size σg
2
0 0.5 1.5 0 0.5 1.5
eRLRT, eScore eRLRT, eScore eRLRT, eScore eRLRT,eScore eRLRT,eScore eRLRT,eScore
Actinobacteria 0.050, 0.038 0.108, 0.075 0.151, 0.100 0.049, 0.038 0.051, 0.048 0.033, 0.040
Bacteroidetes 0.045, 0.040 0.060, 0.055 0.061, 0.055 0.041, 0.040 0.047, 0.042 0.042, 0.037
Firmicutes 0.043, 0.043 0.049, 0.044 0.063, 0.067 0.042, 0.043 0.041, 0.043 0.052, 0.051
Fusobacteria 0.052, 0.048 0.038, 0.041 0.060, 0.048 0.052, 0.048 0.045, 0.044 0.048, 0.037
Proteobacteria 0.051, 0.046 0.041, 0.048 0.056, 0.050 0.049, 0.042 0.040, 0.035 0.053, 0.036
Cross-sectional Design
No Adjustment for Other Adjustment for Other
Phylum Effect Size σg
2 Effect Size σg
2
0 0.5 1.5 0 0.5 1.5
eRLRT, eScore eRLRT, eScore eRLRT, eScore eRLRT,eScore eRLRT,eScore eRLRT,eScore
Actinobacteria 0.041, 0.036 0.117, 0.065 0.111, 0.083 0.050, 0.040 0.052, 0.043 0.048, 0.035
Bacteroidetes 0.051, 0.047 0.048, 0.049 0.051, 0.041 0.051, 0.041 0.048, 0.043 0.048, 0.037
Firmicutes 0.037, 0.038 0.059, 0.052 0.068, 0.062 0.044, 0.038 0.051, 0.045 0.052, 0.048
Fusobacteria 0.053, 0.050 0.070, 0.060 0.078, 0.065 0.052, 0.033 0.051, 0.041 0.048, 0.040
Proteobacteria 0.042, 0.035 0.038, 0.042 0.053, 0.047 0.048, 0.047 0.049, 0.050 0.041, 0.033
Genet Epidemiol. Author manuscript; available in PMC 2020 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Zhai et al. Page 20
TABLE 4
Scenario 3: Comparing to existing methods. Type I error rate and power from eLRT, eRLRT, eScore, 
LinScore, and MiRKAT at baseline when #Repeat = 1. When #Repeat = 2, only LinScore is compared with 
eRLRT and eScore. Sample sizes (n) range from 20 to 100 and effect sizes (σg2) range from 0 to 1:5.
Effect Size σg
2
n #Repeat Method 0 0.10 0.2 0.5 0.8 1.0 1.5
20
1
eScore 0.045 0.059 0.050 0.074 0.078 0.079 0.104
eLRT 0.051 0.089 0.095 0.111 0.118 0.141 0.152
eRLRT 0.050 0.097 0.088 0.108 0.122 0.142 0.160
MiRKAT 0.048 0.056 0.046 0.071 0.069 0.077 0.104
LinScore 0.050 0.060 0.046 0.075 0.072 0.078 0.106
2
eScore 0.050 0.055 0.040 0.057 0.068 0.077 0.088
eRLRT 0.051 0.055 0.074 0.081 0.092 0.085 0.118
LinScore 0.049 0.057 0.063 0.055 0.072 0.078 0.090
30
1
eScore 0.043 0.059 0.050 0.074 0.078 0.079 0.104
eLRT 0.046 0.089 0.095 0.111 0.118 0.141 0.152
eRLRT 0.052 0.097 0.088 0.108 0.122 0.142 0.160
MiRKAT 0.055 0.056 0.046 0.071 0.069 0.077 0.104
LinScore 0.054 0.060 0.046 0.075 0.072 0.078 0.106
2
eScore 0.045 0.058 0.067 0.093 0.114 0.127 0.151
eRLRT 0.052 0.063 0.081 0.105 0.127 0.145 0.178
LinScore 0.046 0.054 0.061 0.076 0.088 0.132 0.134
50
1
eScore 0.036 0.070 0.071 0.118 0.151 0.164 0.240
eLRT 0.048 0.084 0.094 0.135 0.188 0.214 0.306
eRLRT 0.049 0.086 0.088 0.127 0.192 0.201 0.307
MiRKAT 0.047 0.065 0.069 0.114 0.156 0.183 0.257
LinScore 0.045 0.070 0.077 0.124 0.176 0.189 0.267
2
eScore 0.047 0.069 0.084 0.110 0.148 0.177 0.257
eRLRT 0.041 0.074 0.097 0.134 0.188 0.217 0.315
LinScore 0.051 0.063 0.096 0.156 0.205 0.261 0.333
100
1
eScore 0.050 0.096 0.165 0.304 0.383 0.390 0.532
eLRT 0.052 0.114 0.191 0.377 0.472 0.516 0.664
eRLRT 0.049 0.105 0.195 0.375 0.460 0.510 0.661
MiRKAT 0.051 0.093 0.181 0.329 0.427 0.483 0.622
LinScore 0.048 0.106 0.194 0.347 0.439 0.507 0.630
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Effect Size σg
2
n #Repeat Method 0 0.10 0.2 0.5 0.8 1.0 1.5
2
eScore 0.037 0.140 0.205 0.277 0.378 0.411 0.525
eRLRT 0.041 0.161 0.244 0.327 0.447 0.498 0.626
LinScore 0.046 0.121 0.214 0.347 0.451 0.545 0.652
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